網路藥物諮詢問題內容分析研究

全文

(1)An Analysis of the Questions of Online Consumer Medication Information Service. ○.

(2) 2. 2. 13-25 26-35. 2. II!! !. 26-35. 36.

(3) Abstract Due to the development of the Internet, online medical consultation has become another source for consumers to search for medical information. Medication consultation is one of the medical consultation, and drug treatment acts an important role in the course of treatment for the patients. Patients’ health will be improved by following the medical compliance. Based on different demographic differences, the demand for the medical advice are also different. Thus, the research is based on the differences of gender and age, and sets to analyze the expression and behavioral characteristics of the online medication consultation. This study content analyzed 1302 medication consultation questions posted on Taiwan e-Doctor platform, an official online medical consultation service supported by Ministry of Health and Welfare in Taiwan. It is aimed to provide insights and understanding into people’s information need for medication. In the research, the gender shows much more difference through the content and structure of the questions. The female askers are more likely to provide more personal information than the male counterpart shown in the questions. Comparatively, the age illustrates less influence. The questions raised by the female askers show more diversity than the male, but they both focus on the side effects and treatment, indications, and the useage information. The theme that most people concern is similar, but there are slightly different in the secondary category of theme. Askers aged between 13 to 25 years old and the age 36 years old have more question about side effects and treatment than the group between the age 26 to 35 years old. The group between the age 26 to35 years old are more concerned with the classification of drugs than other groups. This study explores the characteristics expression and medication information requirement of each group for medication consultation through the online medication consultation. The results of the study will provide references to users of online medication consultation services, professional medical personnel and drug information providers. Keywords: Online Medication Counseling; Consumer Health Information; Content Analysis. III! ! !.

(4) ............................................................................................................................... V ............................................................................................................................ VII .................................................................................................................. 1 ..................................................................................... 1 ............................................................................................ 4 ............................................................................................ 5 ....................................................................................................... 6. ........................................................................................................... 9 ................................................................... 9 .................................................................... 13 ................................................................................................. 24 ................................................................................... 27. ............................................................................................. 33 ................................................................................... 33 ............................................................................................. 39 .......................................................................................... 41 ..................................................................................................... 48 ............................................................................................. 51 ..................................................................................................... 52. ............................................................................................. 54 ....................................................................................... 54 ................................................................................... 55 .............................................................................................. 62 ....................................................................................... 83 .................................................................................................... 89. ..................................................................................................... 91 ........................................................................................................... 91 .................................................................................................... 93 ........................................................................................................... 93. ......................................................................................................... 96. IV! ! !.

(5) ! 2-2-1. ....................................................................... 18. 2-2-2. ....................................................................... 20. 2-4-1. ................................................................................... 31. 3-1-1. E. ....................................................................... 36. 3-1-2. E. ........................................................... 36. 3-1-3. E. ........................................... 37. 3-3-1. ............................................................... 44. 3-1-2. E ................................................................... 47. 3-4-1. -. .......................................................... 48. 4-1-1. ................................................................................... 55. 4-2-1. ............................................... 55. 4-2-2. ................................................... 57. 4-2-3. ....................... 57. 4-2-4. ................................................... 58. 4-3-5. ....................... 59. 4-3-6. ....................................................................... 60. 4-3-7. ....................................................................... 60. 4-2-8. ............................................................................................... 61. 4-2-9. ................................................................................................... 61. 4-3-1. E. ................................................................................... 62. 4-3-2. ........................................................... 64. 4-3-3. ............................... 64 V! ! !.

(6) 4-3-4. ................................................................... 66. 4-3-5. ................................................................... 67. 4-3-6. ............................................................................... 70. 4-3-7. ........................................................... 75. 4-3-8. ............................................................... 81. 4-3-9. ................................... 83. 4-4-1. ....................................................................... 84. 4-4-2. ....................................................................... 87. 4-4-3. ............................................................... 89. VI! ! !.

(7) ! 1-3-1. ............................................................................. 6. 2-2-1 Druginfonet. .......................................................................................... 14. 2-2-2 drugs.com. ............................................................................................. 14. 2-2-3 WebMD. ................................................................................................ 15. 2-2-4 RateADrug 2-2-5 2-2-6. ............................................................................................ 16 -. E. .......................................... 16 ............................................................................... 17. 2-2-7 KingNet. ................................................................................ 17. 2-2-8 5914. .............................................................................................. 18. 2-4-1. ................................................................... 28. 2-4-2. ................................................................................... 30. 3-1-1. E. ............................................................................... 35. 3-1-2 3-1-3. ....................................................................................... 35 Q&A. ............................................................................ 36. 3-2-1. ................................................................................................... 40. 3-5-1. ........................................................... 52. 4-1-1. E. ........................................................... 54. VII! ! !.

(8) !. !. !. 2 0. 2. E. 93 American Pharmacy. 2000 1774. 1995. 766. 2002. 5. 2002 8. 1 2008. medication error adverse effect 1!! !. 2.

(9) 2015. 90%2. 2014. 2015 2015. 2 2016 medication error adverse effect. 2002 2012. 1,093 1. 4. 2 2012. 2!! !.

(10) !. 2. 2012. Hermann et al., 1978; Vander Stichele et al., 1991; Bandesha et al.,1996; Baker, 1997. Wolf. Davis. Tilson. Bass III. Parke 2006. 2 The Association of British Pharmaceutical Industry, ABPI. 2 Gazmararian, Baker,. Williams, Parker, Scott, Green. Koplan, 1999. Schillinger, Grumbach, Piette, Wang, Osmond, Daher. Bindman, 2002. 2. 2004 3!! !.

(11) Johnson. Deering & Harris. 1993. 1996. 2. 2 25. 44. 2004. Spink et al., 2004; Zeng et al., 2006. Oh, Yi, & Worrall,. 2 2012. !. !. ! 2. 2. 4!! !.

(12) 2 2 2 2. ! 1. 1-1 1-2 2.. 2-1 2-2 3.. 3-1 3-2. !. !. ! 3. web1.0. 5!! !.

(13) E. Kingnet 5914. Kingnet. ! 2. 1-3-1. 2. 2. 1-3-1. !. !. 6!! !.

(14) Adherence or Compliance. Sabaté, 2003. Haynes. Taylor. !. 1979. E. !. Patient Counseling 2001. 11. 48 (1). (2). (3). (4). (5) (6). (7). (8). (9). 2. (10). (11). 2 2. 0. /. 16. Online Pharmacy Consultation Food and Drug Administrations. Zeman, 2001. wiseGeek. E. 7!! !. !.

(15) Medicine Information Needs Ocheibi. !. Buba 2003 2. Raynor, Savage, Knapp & Henley, 2004. Health belief. !. Health Belief Model. 1950. 2. Social Q&A. !. web2.0. 2 Shah, Oh & Oh. 2009. (1) (2). 2 (3) 2. 8!! !.

(16) !. !. !. !. ! ! Wolf. Sangl 1996. 1. 2 3. 4. Elliot & Polkinhorn (1994) Consumer Health Information. Medical Library Association. Consumer and. Patient Health Information Section of Medical Library Association. Consumer and Patient Health Information Section of Medical Library Association, 1996 60. 0. 2. 9!! !.

(17) Patient Information Deering & Harris. 1996 1. Medical instructions. 2. Decision support information. 3. Medical records. 4. Health education 5. 2. Self-care information 2. 6. Health care shopping information Quality in care information 7. Alternative medicine. 0 The Pew Internet Project. 59%. 80% Fox, 2011. 2002 1.. 3.. 2.. 4.. 5.. 6.. 7. 8.. 9.. 10.. 10! ! !.

(18) Sangl &. 2 Wolf, 1996. Zhang, 2010. ;. 2 Deering & Harris, 1996. 2 2 2010. !. Renahy, Parizot & Chauvin, 2010 Life Project. Pew Research Center’s Internet & American. 2013. Rice, 2006. 81%. 59 Fox & Duggan, 2013. 0. 2. 2. 3. 11! ! !.

(19) architectural difference. 2. digitization of information 2010 30. —. 2. Barak & Grohol, 2011. “end-user” value. 53.9% 43.2%. 55.6%. 26.7%. 80% 65% 2007 0 2. 2. 2003. Harris. 1995. 2. KingNet 92. 1,501. 2 12! ! !.

(20) e-mail. 2. ! 2. !. !. !. 3. Hepler & Strand, 1990 3. 2. Cockerham 2004 E 2. 2. 2 2. Druginfonet http://www.druginfonet.com/ Official Package Inserts 13! ! !. Patient Package Inserts.

(21) FDA. 2-2-1 Druginfonet drugs.com https://www.drugs.com/answers/ 2400. 2. webMD Health Corp.. Q&A Center. 2-2-2 drugs.com WebMD http://www.webmd.com/drugs/index-drugs.aspx WebMD. 14! ! !. drugs.com.

(22) Drugs & Supplements A. Z. 2-2-3 WebMD RateADrug http://www.rateadrug.com/. RateADrug.com “Evaluate Your Treatment”. 15! ! !.

(23) 2-2-4 RateADrug http://203.75.23.71/Drug_guide.aspx. 2. 2-2-5. -. E E. 16! ! !.

(24) 2-2-6. E KingNet. KingNet. 68. 30 38. 6. 20. 2-2-7 KingNet 5914. 17! ! !.

(25) 24. 2-2-8 5914 0. 2 2 A-Z. RateDugs. 2-2-1. 2-2-2. 2-2-1. Druginfonet Drugs.com OTC. WebMD 18! ! !. 2.

(26) RateADrug. MedCheck -. E. KingNet. 5914. 19! ! !.

(27) 2-2-2. A. 2 Druginfonet. A. A. 0. ! 20! !. Drugs.com. WebMD. RateADrug.

(28) 0 2 .. ! 21! !.

(29) E. 2. e. s. L. 22! ! !. KingNet. 5914.

(30) 23! ! !.

(31) 1. !. !. . ◎ Health Decision Model. (. ◎. h. Health Belief Model. t. patient preference. ,. ( 1.. 2000. t. (perceived susceptibility). t. :. (perceived seriousness). (2. 4. (perceived benefits). (3. a 5. :. 4. (perceived barriers). (4.. 4 (other variables). (5.. p. e. (modifying factors). (cues to action)(. (6. (. ◎. 2 .. (. ◎ .. e. 4 World Health Organization [WHO], 2003 4. (. 1.. . 24! ! !. (.

(32) 2.. e2. p. (3.. 2. (4.. e. 65. e 2. (5. (. 1.. (2.. (3.. t. ◎. l. (4.. (. !. E. compliance,. compliance. U. .. adherence,. compliance. (. 2. MacLaughlin, Raehl, Treadway, Sterling, Zoller & Bond, 2005. patient empowerment. ◎. : ◎. 4 ,. . .. ( 4. (. 1972. Blackwell 4. Patient Education Conferences. ( 4. 4. 4 Nichols-English & Poirier, 2000. ~. (3. 4. Hussar, 1975 ! t p. 4. (. !. 4 (. 25! ! !. 2.

(33) ! 4. 2(. ! ( ! x !. (. e. e ~. !. (. e e. !. 4. (. (. ! a !. ( ( 4. ◎ ◎. 3. e e Crichton, Smith & Demanuele, 1978. (. 2 Lee,. t 1979. Makoul, Arntson & Schofield, 1995. (. a (. . a. : 2016. 26! ! !. (.

(34) ! !. .. l!. ! ◎ p. l. 3 4 (. 2 Morris, 1987 (. ◎. 36.2%. : 5.2%. 3.6%. 2002. 7.4%. 1.97%. 37.7%. (. 11.3%. 4. 7.7%. e 2004. 13% 2002. e. 36.3%. (. 30.6%. 4. 4. (. 5. (. Nair. 2002 e. 5. e. l. (. ◎. 54.4%. 2 4. 33%. e. 1 e 3. 6 2-4-1. (. 27! ! !.

(35) 2-4-1 Nair, K., Dolovich, L., Cassels, A., McCormack, J., Levine, M., Gray, J., ... & Burns, S. (2002). What patients want to know about their medications. Focus group study of patient and clinician perspectives. Canadian Family Physician, 48(1), 104-110. 4. t. . :. E . ( .. 3 .. .. .. p. E Morris & Halperin, 1979. p. 2 28! ! !.

(36) 5 Davis, Wolf, Bass, Middlebrooks, Kennen, Baker... & Parker, 2006. (. lay source. Raynor, Savage, Knapp & Henley,. W 2004. (. .. . 20. 70. 29. 3.47 1.42. 2 2001. 5 50~60. 4. ( health locus of control. health literacy levels 2006. Koo, Krass & Aslani,. ( What patients want to know about their medications. Focus group study of. patient and clinician perspectives.. Nair et al., 2002. .. .. .. (. Ascione, Kirscht & Shimp, 1986 : ,. o. ,. , e. ,. ,. , ,. .. e. e ,. e. 5 2004. E. (. l! 5. l social network 2-4-2. ◎. Wallace, Roskos & Weiss, 2006. 4 29! ! !. (.

(37) 2-4-2 The American College of Physicians Foundation(ACPF),. 2007. :. ◎ 2007. 6. Davis 2001 ( P. (. 4 European. Commission. 1997. verbal. . 5. 10%. very common common. 1. 10%. rare 0.01 0.1% 2002. 4. very rare )0.01%( U. 30! ! !. common. 3. 2-4-1. U.

(38) 2-4-1. . s e 0910033863 GDP. 31! ! !.

(39) e. Shrensky & Sless. 2008 Preference Tests. Expert Opinion. Focus Group. 6. Diagnostic Testing (. :. y. 2010. (. ! l. :. 2. l .. (. , 2 ( ◎ (. 2 2 e. 32! ! !. (!.

(40) 1 !. ! .. (. E. ,. ,. P. ,. (. 1. (. , ( y. y. ,. (. .. !. !. .. manifest content latent content. Downe-Wamboldt, 1992. (. Berelson, 1952 .. 5 (. Krippendorff, 1980 (. :. ,. ,. ,( ( :. Hsieh & Shannon, 2005 : 2007; Hsieh & Shan-non, 2005. (. ◎ Krippendorff. 2 !. Houldin,. 1980. 3 :. E. ,. 33! ! !. e. (.

(41) !. : (. !. E. ( !. . 1300. (. ( !. E. 2016. 32. (. !. 6 1. 6. (. !. E. E. (. 3. ( . E 33 22. 6. 240. ◎. 2. 2. 6. : E. (. l. s 6. ◎. ( E. ( l 34. 3-1-1. (. python beautifulsoup beautifulsoup. .. excel. 2. python. HTML XML . Crummy, 2012. p 34! ! !. :.

(42) E http://taiwanedoctor.mohw.gov.tw/. 3-1-1. HTML. Q&A. 3-1-2. XML 4. ,. .. Excel .. 2016 1302. 4. Excel. 4 1272. 3-1-1. E. 3-1-2. 35! ! !. (.

(43) 3-1-3 3-1-1. Q&A. E. -. A E 3-1-2. 32. , (. 3-1-2. E. ,. e. e. / s. :. s s. -. A. 36! ! !. -.

(44) 3. .. 3-1-3. E. (. e : 2003 3-1-3. 6. 2016. 4. (. (. E. ,. s. c. A. A. 37! ! !.

(45) A. FM-2 A. A. E excel .. .3. 2. E. p b. 1. .. 2. 2. 2 4. .. . p 6. 2 38! ! !. t (.

(46) E. !. !. .. . .. E l. 4. ( 3-2-1. : :. ( 50 4 ( p. (. 39! ! !.

(47) ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !. 7. 8 7. 1. ) 3. 1. ). 3-2-1. 40! ! !.

(48) 1.!. :. 2 2. :. (. l . l. (. e 2.!. (. : 2. 1. :. 6 (. 3.! ( 4.! 6. (. 5.!. 50 ( 6. (. 6.!. 6. 4 (. 7.!. 2.. 6. (. 8.! (. 1. !. 3. ( E. Excel Anselm Strauss. ( 41! ! !. 1998.

(49) ,. ,. ,. ,. 2. 6 6 :. (. . 2. E. 1 : ( . Johnson t. t. (. (. ◎ Deering & Harris 1996. (. E. 2013 5 ( WesemannD2007E. Grunwald. 4. 4 4 4. ( 4. 42! ! !. 4.

(50) ◎. 2. 1. 2. : f 2016. 16. : E. 2. ( :. 4. .. 26~35. :. 18~25. .. e. 4. (. t. Individual Perception. Cues to Action (. Cues to Action Individual Perception. ( 1. Perceived Susceptibility. : :. .. : (. 4 2. 4. Perceived Severity. :. ( ◎. : :. (. ( Perceived Benefits of Taking Action. :. a 4. 3. ( l. 2 43! ! !. 1.

(51) t. a. ( 4. ( Perceived Barriers of Taking Action. :. (. p. e 4. (. E 2. 3-3-1(. 3. 3-3-1. 1. .. E 1. 2. ◎ 1 , , ,. ,. ,. .. ◎ ◎ 1. 44! ! !. :.

(52) :. e. e. e. A e. e. s. s. s. h s. s E e. (. 45! ! !.

(53) 2. 2. l. 2. a. 2 3-1-2 ,. 2 ?,. ◎ :. 2. e 2. ?,. . ?, 46! ! !.

(54) 2. ,. ,. 2. ( 3-1-2. V. ◎. V ??. :. V. e 3. X. X. . ??. 71. X. 2. V. 1 Excel. SPSS. 3. .. l ,. ,. e (. E. ( ( 47! ! !.

(55) 4 ( 1. E. E. 2. (. ( (. ! 50. (. 50 : ( 3-4-1. : ( 3-4-1. -. :. e. e. e. e. ) e A A A. 48! ! !.

(56) Off Label Use. 4 3 Amoxicillin500mg Acetaminophen500mg Danzen 4. 4 ( 5MG E. PURCON b 1. CONCOR 5. (. glucophage. humatrope. Lowen0.5mg. 49! ! !. 4 Suweilin.

(57) 3mg . FM2(1mg). . p. 4. 4 p. Pentoxifylline theophylline .. A. 4. 3. . 2. E. . .. .. 2 Trimyzole. ~. mg EconazoleNitrate10mg TriamcinoloneAcetonide1mg. e. e. 4. ?. e s. s. s. . s. 50! ! !.

(58) h. 4 (. s. s .. .. .. 4 4. . 4. 2 s (. 40%. 21~30. 31~40 13-20. 38%. 36. 21-30. 31-40. 40. 40% 13-25. 2. 1302. 2. 60%. 50. c (. !. t. t. 4. Neuendorf, 2002. . 1. .. (. 2 .. a. 4. (. t. 3-5-1. :. 4. .. .. t. .. t a(William M.K. Trochim. t. . 4. 2001 .. .. (. 51! ! !. 26-35.

(59) 3-5-1 Cohen Kappa t. 3. P0. .. (observed agreement). Pc. .. (chance agreement). Kappa. P. -1 ~ 1. (. (Neuendorf 10. (. ). (. ). 0.8. 2. 2002. .. t. 0.8. 2. 50. 30 t. 3. t. 1300 4. 0.6. 100. (. t (. . 0.86. ( t. (. !. y 5. e. y. 52! ! !. P (.

(60) :. s. 4 1992. t & Wallen, 1996; Redestam & Newton, 1992; Tuckman, 1994 2. (. ( E. 2. e. e(, 6. Fraenkel. n. E. e. 2 (. 53! ! !. E.

(61) ! !. !. 2. ( e. E. 1. .. .. 1 (!. 1302 30. 30 30. 4. 64. (. (. ,. 4-1-1. (. 846. 66%. 34% 458. (13-25 41%. 2. 4-1-1. 1272 426. ,. 36. 36% 287. 2. (. 4-1-1. E. 54! ! !. 26-35 23%. 527 ..

(62) 4-1-1. 426. 33.5%. 846. 66.5%. 13-25. 458. 36%. 26-35. 527. 41.4%. 287. 22.6%. 36. 2. E. 4-2-1(. , , ,. ,. ,. ,. ,. , ,. ( 4-2-1. xanax. ? xanax. ?. ,. 4. ?. e. , .. .3. ... ◎ ?. 1. 55! ! !.

(63) 0 , .. ,. ,. PRIMPERAN) 2. , , .. Excel =LENB(B2)LEN(B2) xanax ? ,. 4. e. ?. . 4 e E. l 2. (. 2. 4. 2. 3 H0:. 4. 2. 2. H1:. 4. 2. 2. 2. 4. ( ( 2. 3 H0:. 4. 2. 2. ( 56! ! !.

(64) H1:. 4. 2. 2. 4-2-2. 4-2-3. 4. e. e χ2(2). 4.147. χ2(3). 0.003. χ2(3). p=.91 p=.866 p. 0.013. χ2(3). 0.038. (. 1.544. χ2(2). p=.462 p=.126 p=.956. 0.05. 64 . (. 4-2-2 4 13-25. 69. 66. 31.8%. 26-35. 91. 66. 36.9%. 70. 63. 31.3%. 230. 195. 13-25. 166. 157. 38.1%. 26-35. 217. 154. 43.8%. 79. 74. 18.1%. 385. 462. 13-25. 235. 223. 36%. 26-35. 308. 220. 41.5%. 149. 137. 22.5%. 692. 580. 54.4%. 45.6%. 36. 36. 36. 2. 2. 2. 4-2-3. 57! ! !. 1.544. 2. .462. 4.147. 2. .162.

(65) 13-25. .003. 1. .956. 26-35. .013. 1. .91. .028. 1. .866. 36. 2. p<0.05. E 4 e E. l 2. (. 2. 4. 2. 3 H0:. 4. 2. 2. H1:. 4. 2. 2. 2. 4. H0:. ( ( 2. 4. 2. 2. 4. 2. 2. ( H1:. (. 4-2-5. 2. !2. 2. =8.672. n=277. p<0.05. 6. a. 2. 26-35. ( 2. 2. 4. 4 4. ( (. 4-2-4. 58! ! !. 26-35. a. 4.

(66) 4 13-25. 87. 48. 31.8%. 26-35. 111. 46. 36.9%. 85. 48. 31.3%. 283. 142. 13-25. 215. 108. 38.1%. 26-35. 277. 94. 43.8%. 97. 56. 18.1%. 385. 462. 13-25. 156. 302. 36%. 26-35. 140. 388. 41.5%. 182. 104. 22.5%. 872. 400. 31.4%. 68.6%. 36. 36. 36. 2. 2. 2. 4-3-5. 1.901. 2. .387. 8.672. 2. .013. .004. -. .387. .010. -. .013. .067. -. .387. .101. -. .013. 13-25. .190. 1. .663. 26-35. .889. 1. .346. .008. 1. .929. .000. -. .663. Tau. 36 Tau. 2. 13-25 59! ! !.

(67) .002. -. .346. .000. -. .929. 13-25. .020. -. .663. 26-35. .041. -. .346. .005. -. .929. 26-35 36. 36. 2. 2. p<0.05. 1 4-3-6. 4-3-7. 86. 6.8% 2. 4. 2 26-35. ( 4-3-6. 29. 396. 2.3%. 31.1%. 57. 790. 4.5%. 62.1%. 86. 1186. 29. 429. 2.3%. 33.7%. 40. 488. 3.1%. 38.4%. 17. 269. 1.3%. 21.1%. 33.4%. 66.6%. 4-3-7. 13-25. 26-35. 36. 2. 60! ! !. 36%. 41.5%. 22.5%.

(68) 86. 1186. 4-2-8. 6 91. 2 92. 13-25 94. 97. 36. 26-35 79. 2 13-25. 2. 26-35. 36. 2. (. 4-2-8. 425. 90.84. 874. 92.41. 13-25. 458. 94.37. 26-35. 528. 96.5. 286. 79.38. 36. 2. 4-2-9. 4. 1.9. 2.09 2.19 36. 4. 26-35. 1.99 1.84. 2 1. (. 4-2-9. 425. 1.91. 874. 2.09. 13-25. 61! ! !.

(69) 13-25. 458. 2.19. 26-35. 528. 1.99. 286. 1.84. 36. 2. 1 2 Nair. 2002 e. ,. :. :. ,. ,. ,1. 4 ,. ,. . 4. : .. (. .. , (. ◎. ,. 1. ,. , 4-3-1(. 2. 4-3-1. ˙. ... ... . ... 4. 4 e (. 62! ! !.

(70) ◎. 6. O. ,. , allegra(60mg)0.5 bid,transamin(250mg)0.5 bid, allerga 12 2 ,O 6 ? O 4 6 , 4 64 ? !! .. , ,. ( , ,. ,. 1 .. .3. ... ? ? (. normosanginj( ?. ). .. 2 (. 4-3-2. 4. 53.7% 70%. c. ◎. 13.6%. 2%. 30.7%. E. t. 2. (. 8 ( 209/. C / 2. 36. C. 4-3-3 2 Tau=.011. . χ2. 6. =17.357. p<0.05. .. =.142 1363! ! !.

(71) 25. 26-35. 26-35. 13-25. ,. =212. =182 4. , 64. (. (. 4-3-2 ◎ 13-25. 70. 11. 5. 49. 31.8%. 26-35. 85. 24. 5. 43. 36.9%. 70. 16. 1. 46. 31.3%. 225. 51. 11. 138. 13-25. 182. 35. 6. 100. 38.1%. 26-35. 212. 59. 7. 93. 43.8%. 64. 28. 2. 59. 18.1%. 458. 122. 15. 252. 13-25. 252. 46. 11. 149. 36%. 26-35. 297. 83. 12. 136. 41.5%. 134. 44. 3. 105. 22.5%. 683. 173. 26. 390. 53.7%. 13.6%. 2%. 30.7%. 36. 36. 36. 2. 2. 2. 4-3-3. 7.796. 6. 17.357. 6. .004. -. .011. -. .134. -. Tau. 64! ! !. .253 .008 .459 .000 .253.

(72) .142. -. 13-25. 3.219. 3. .359. 26-35. 1.252. 3. .741. 4.106. 3. .25. 13-25. .002. -. .406. 26-35. .001. -. .821. .007. -. .117. 13-25. .084. -. .359. 26-35. .049. -. .741. .119. -. .25. 36 Tau. 36. 36 p<0.05. p<0.01. 2. 2. 2. .008. p<0.001. 4-3-4. e. (. ◎. e 4. ◎. 1. 69. c. 25-36. 1. c. 64. 115. 65! ! !. 25-36. 1.

(73) 4-3-4 ◎ e. c. c. c. c. c. c. c. c. c. c. c e. c. 1. 255. 67. 6. 109. 437. 20.0%. 5.3%. 0.5%. 8.6%. 34.4%. 12. 5. 0. 7. 24. 0.9%. 0.4%. 0.0%. 0.6%. 1.9%. 32. 8. 1. 8. 49. 2.5%. 0.6%. 0.1%. 0.6%. 3.9%. 6. 8. 0. 4. 18. 0.5%. 0.6%. 0.0%. 0.3%. 1.4%. 81. 23. 3. 42. 149. 6.4%. 1.8%. 0.2%. 3.3%. 11.7%. 27. 14. 0. 32. 73. 2.1%. 1.1%. 0.0%. 2.5%. 5.7%. 140. 32. 5. 110. 287. 11.0%. 2.5%. 0.4%. 8.6%. 22.6%. 153. 32. 6. 78. 269. 12.0%. 2.5%. 0.5%. 6.1%. 21.1%. 70. 23. 2. 54. 149. 5.5%. 1.8%. 0.2%. 4.2%. 11.7%. 118. 37. 7. 60. 222. 9.3%. 2.9%. 0.6%. 4.7%. 17.5%. 91. 12. 2. 14. 119. 7.2%. 0.9%. 0.2%. 1.1%. 9.4%. 31. 5. 0. 18. 54. 2.4%. 0.4%. 0.0%. 1.4%. 4.2%. 3. 1. 0. 7. 11. s. 66! ! !.

(74) ◎. 1. 0.2%. 0.1%. 0.0%. 0.6%. 0.9%. 37. 11. 4. 38. 90. 2.9%. 0.9%. 0.3%. 3.0%. 7.1%. 19. 11. 1. 22. 53. 1.5%. 0.9%. 0.1%. 1.7%. 4.2%. 12. 6. 0. 4. 22. 0.9%. 0.5%. 0.0%. 0.3%. 1.7%. 683. 173. 26. 390. 1272. 53.7%. 13.6%. 2.0%. 30.7%. 100.0%. c h. c s. c. c. c. 4-3-5 64 4 ◎. 1. l. ◎. (. c. 3. 2. .. 4. /. 3. / 947. 4. 36. 2 4-3-5 ◎ c c c. 1. 171. 48. 4. 140. 363. 13.4%. 3.8%. 0.3%. 11.0%. 28.5%. 11. 0. 0. 4. 15. 0.9%. 0.0%. 0.0%. 0.3%. 1.2%. 7. 1. 1. 5. 14. 0.6%. 0.1%. 0.1%. 0.4%. 1.1%. 2. 28. 0. 9. 39. 67! ! !.

(75) c c c c c c c c c c c c. E. ◎. 1. 0.2%. 2.2%. 0.0%. 0.7%. 3.1%. 11. 10. 3. 11. 35. 0.9%. 0.8%. 0.2%. 0.9%. 2.8%. 9. 1. 0. 3. 13. 0.7%. 0.1%. 0.0%. 0.2%. 1.0%. 3. 3. 0. 2. 8. 0.2%. 0.2%. 0.0%. 0.2%. 0.6%. 72. 15. 1. 26. 114. 5.7%. 1.2%. 0.1%. 2.0%. 9.0%. 16. 2. 1. 7. 26. 1.3%. 0.2%. 0.1%. 0.6%. 2.0%. 101. 18. 6. 102. 227. 7.9%. 1.4%. 0.5%. 8.0%. 17.8%. 177. 22. 4. 27. 230. 13.9%. 1.7%. 0.3%. 2.1%. 18.1%. 30. 14. 2. 18. 64. 2.4%. 1.1%. 0.2%. 1.4%. 5.0%. 58. 7. 3. 30. 98. 4.6%. 0.6%. 0.2%. 2.4%. 7.7%. 15. 4. 1. 6. 26. 1.2%. 0.3%. 0.1%. 0.5%. 2.0%. 683. 173. 26. 390. 1272. 53.7%. 13.6%. 2.0%. 30.7%. 100.0%. : l 4. .. :. : c0. c1 4-3-6. 2 13-25 n=113 :. n=180. e n=98 e. 2 e 68! ! !. (.

(76) / 3 ?. B 13-25. 243 26-35. e. 1. .. A. (. 1 387 36. 5 26-35. 2. e. 1. e. /. h. :. 325. 36. .. 2. :. 2 36. , 2. B. . 230 69! ! !. 36. 2. 64.

(77) 0. 639. C. 36. 2. : e 2. : :. 4. 13-25. 26-35. e. 36. 26-35. ( 4-3-6. 13-25. :. e c. c. c. c. c. c. c. c 70! ! !. 48. 132. 180. 10.5%. 28.8%. 39.3%. 5. 4. 9. 1.1%. 0.9%. 2.0%. 5. 13. 18. 1.1%. 2.8%. 3.9%. 1. 2. 3. 0.2%. 0.4%. 0.7%. 26. 40. 66. 5.7%. 8.7%. 14.4%. 8. 14. 22. 1.7%. 3.1%. 4.8%. 39. 74. 113. 8.5%. 16.2%. 24.7%. 25. 73. 98. 5.5%. 15.9%. 21.4%.

(78) c. c. c e c s c h c s c. c. c 26-35. e c. c. c. c. 71! ! !. 16. 44. 60. 3.5%. 9.6%. 13.1%. 19. 59. 78. 4.1%. 12.9%. 17.0%. 4. 15. 19. 0.9%. 3.3%. 4.1%. 0. 14. 14. 0.0%. 3.1%. 3.1%. 0. 3. 3. 0.0%. 0.7%. 0.7%. 15. 22. 37. 3.3%. 4.8%. 8.1%. 4. 15. 19. 0.9%. 3.3%. 4.1%. 1. 7. 8. 0.2%. 1.5%. 1.7%. 135. 323. 458. 29.5%. 70.5%. 100.0%. 46. 104. 150. 8.7%. 19.7%. 28.4%. 3. 9. 12. 0.6%. 1.7%. 2.3%. 5. 9. 14. 0.9%. 1.7%. 2.7%. 4. 6. 10. 0.8%. 1.1%. 1.9%.

(79) c. c. c. c. c. c. c e c s c h c s c. c. c. 72! ! !. 14. 39. 53. 2.7%. 7.4%. 10.0%. 6. 29. 35. 1.1%. 5.5%. 6.6%. 42. 69. 111. 8.0%. 13.1%. 21.0%. 43. 69. 112. 8.1%. 13.1%. 21.2%. 16. 39. 55. 3.0%. 7.4%. 10.4%. 25. 73. 98. 4.7%. 13.8%. 18.6%. 7. 75. 82. 1.3%. 14.2%. 15.5%. 10. 15. 25. 1.9%. 2.8%. 4.7%. 1. 3. 4. 0.2%. 0.6%. 0.8%. 12. 16. 28. 2.3%. 3.0%. 5.3%. 8. 16. 24. 1.5%. 3.0%. 4.5%. 3. 9. 12. 0.6%. 1.7%. 2.3%. 157. 371. 528. 29.7%. 70.3%. 100.0%.

(80) 36 2. e c. c. c. c. c. c. c. c. c. c. c e c s c. 73! ! !. 44. 63. 107. 15.4%. 22.0%. 37.4%. 1. 2. 3. 0.3%. 0.7%. 1.0%. 10. 7. 17. 3.5%. 2.4%. 5.9%. 3. 2. 5. 1.0%. 0.7%. 1.7%. 16. 14. 30. 5.6%. 4.9%. 10.5%. 7. 9. 16. 2.4%. 3.1%. 5.6%. 25. 38. 63. 8.7%. 13.3%. 22.0%. 27. 32. 59. 9.4%. 11.2%. 20.6%. 21. 13. 34. 7.3%. 4.5%. 11.9%. 18. 28. 46. 6.3%. 9.8%. 16.1%. 4. 14. 18. 1.4%. 4.9%. 6.3%. 9. 6. 15. 3.1%. 2.1%. 5.2%. 1. 3. 4. 0.3%. 1.0%. 1.4%.

(81) h c s c. c. c. 74! ! !. 14. 11. 25. 4.9%. 3.8%. 8.7%. 5. 5. 10. 1.7%. 1.7%. 3.5%. 0. 2. 2. 0.0%. 0.7%. 0.7%. 133. 153. 286. 46.5%. 53.5%. 100.0%.

(82) 4-3-7 / 123. 5. 5. 8. 4. 6. 1. 50. 8. 61. 72. 29. 54. 11. 33.9 %. 33.3 %. 35.7 %. 20.5 %. 11.4 %. 46.2 %. 12.5 %. 43.9 %. 30.8 %. 26.9 %. 31.3 %. 45.3 %. 55.1 %. 42.3%. 6. 5. 0. 1. 0. 0. 5. 0. 0. 2. 3. 2. 0. 0. 1.7 %. 33.3 %. 0.0 %. 2.6%. 0.0 %. 0.0 %. 62.5 %. 0.0%. 0.0%. 0.9%. 1.3%. 3.1%. 0.0%. 0.0%. 18. 2. 0. 2. 2. 1. 0. 4. 3. 3. 7. 4. 3. 0. 5.0 %. 13.3 %. 0.0 %. 5.1%. 5.7 %. 7.7 %. 0.0%. 3.5%. 11.5 %. 1.3%. 3.0%. 6.3%. 3.1%. 0.0%. 16. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 4.4 %. 0.0 %. 0.0 %. 0.0%. 0.0 %. 0.0 %. 0.0%. 0.0%. 0.0%. 0.9%. 0.0%. 0.0%. 0.0%. 0.0%. 52. 2. 1. 5. 2. 0. 1. 16. 3. 22. 21. 4. 16. 4. 14.3 %. 13.3 %. 7.1 %. 12.8 %. 5.7 %. 0.0 %. 12.5 %. 14.0 %. 11.5 %. 9.7%. 9.1%. 6.3%. 16.3 %. 15.4%. 27. 0. 1. 2. 2. 1. 0. 9. 4. 15. 5. 5. 2. 0. 7.4 %. 0.0 %. 7.1 %. 5.1%. 5.7 %. 7.7 %. 0.0%. 7.9%. 15.4 %. 6.6%. 2.2%. 7.8%. 2.0%. 0.0%. 84. 3. 4. 9. 12. 3. 0. 41. 6. 53. 28. 18. 20. 6. ! 75! !. 437. 24. 49. 18. 149. 73. 287.

(83) / 23.1 %. 20.0 %. 28.6 %. 23.1 %. 34.3 %. 23.1 %. 0.0%. 36.0 %. 23.1 %. 23.3 %. 12.2 %. 28.1 %. 20.4 %. 23.1%. 72. 3. 2. 11. 5. 1. 1. 20. 9. 47. 48. 16. 29. 5. 19.8 %. 20.0 %. 14.3 %. 28.2 %. 14.3 %. 7.7 %. 12.5 %. 17.5 %. 34.6 %. 20.7 %. 20.9 %. 25.0 %. 29.6 %. 19.2%. 42. 2. 2. 5. 6. 1. 1. 17. 2. 40. 13. 5. 8. 5. 11.6 %. 13.3 %. 14.3 %. 12.8 %. 17.1 %. 7.7 %. 12.5 %. 14.9 %. 7.7%. 17.6 %. 5.7%. 7.8%. 8.2%. 19.2%. 63. 2. 5. 13. 11. 6. 1. 21. 5. 41. 30. 6. 15. 3. 17.4 %. 13.3 %. 35.7 %. 33.3 %. 31.4 %. 46.2 %. 12.5 %. 18.4 %. 19.2 %. 18.1 %. 13.0 %. 9.4%. 15.3 %. 11.5%. 5. 0. 0. 4. 0. 0. 0. 5. 0. 4. 97. 0. 4. 0. 1.4 %. 0.0 %. 0.0 %. 10.3 %. 0.0 %. 0.0 %. 0.0%. 4.4%. 0.0%. 1.8%. 42.2 %. 0.0%. 4.1%. 0.0%. 22. 1. 1. 2. 1. 1. 0. 3. 1. 3. 2. 5. 11. 1. 6.1 %. 6.7 %. 7.1 %. 5.1%. 2.9 %. 7.7 %. 0.0%. 2.6%. 3.8%. 1.3%. 0.9%. 7.8%. 11.2 %. 3.8%. 4. 0. 0. 0. 0. 0. 0. 2. 0. 4. 1. 0. 0. 0. 1.1 %. 0.0 %. 0.0 %. 0.0%. 0.0 %. 0.0 %. 0.0%. 1.8%. 0.0%. 1.8%. 0.4%. 0.0%. 0.0%. 0.0%. 41. 0. 0. 1. 1. 0. 1. 5. 2. 17. 5. 5. 11. 1. ! 76! !. 269. 149. 222. 119. 54. 11. 90.

(84) / 11.3 %. 0.0 %. 0.0 %. 2.6%. 2.9 %. 0.0 %. 12.5 %. 4.4%. 7.7%. 7.5%. 2.2%. 7.8%. 11.2 %. 3.8%. 12. 1. 1. 1. 1. 0. 1. 5. 1. 23. 3. 1. 1. 2. 3.3 %. 6.7 %. 7.1 %. 2.6%. 2.9 %. 0.0 %. 12.5 %. 4.4%. 3.8%. 10.1 %. 1.3%. 1.6%. 1.0%. 7.7%. 6. 0. 0. 1. 0. 0. 1. 0. 0. 11. 2. 1. 0. 0. 1.7 %. 0.0 %. 0.0 %. 2.6%. 0.0 %. 0.0 %. 12.5 %. 0.0%. 0.0%. 4.8%. 0.9%. 1.6%. 0.0%. 0.0%. 363. 15. 14. 39. 35. 13. 8. 114. 26. 227. 230. 64. 98. 26. 1272. 28.5 %. 1.2 %. 1.1 %. 3.1%. 2.8 %. 1.0 %. 0.6%. 9.0%. 2.0%. 17.8 %. 18.1 %. 5.0%. 7.7%. 2.0%. 100.0 %. ! 77! !. 53. 22.

(85) 4-3-7 28.5%. 18.1%. 17.8%. 3 . -. 710/. 1. 13-25. 2010. 10% " 808. 42.2%. " 24. 26-35. 78! ! !. 13-25. 2.

(86) (. 0 1. 119. 13-25. 2 (. ). 143. 26-35. ( ,. !. E. / / 4-3-9. !2 13-25. =. 26. =53.671 p<0.001. 4-3-8. 36. 26-35. 13-25. 26-35. 36. 13-25. !2 13-25. =. 26. =53.671. p<0.01. 4-4-. 26-35. 36. !2(13) 36.562. 13-25 p=.000. !2(13) 55.336 p=.000 !2(13) 30.221 p=.004 Tau=.011 =.335. Tau=.01. /. =.235. 13-25 79! ! !. /.

(87) 26-35 36 26-35. 80! ! !.

(88) 4-3-8. 13~25. 51. 4. 1. 12.0% 0.9% 0.2%. 26~35. 42. 4. 3. 9.9% 0.9% 0.7%. 36~. 51. 1. 2. 12.0% 0.2% 0.5%. 144. 9. 6. 33.9% 2.1% 1.4%. 13~25. 91. 3. 6. 10.7% 0.4% 0.7%. 26~35. 83. 2. 2. 0. 0. 0. 21. 3. 26. 11. 8. 3. 7. 0.0% 0.0% 0.0%. 0.0%. 4.9%. 0.7%. 6.1%. 2.6%. 1.9%. 0.7%. 1.6%. 3. 1. 11. 8. 36. 13. 9. 16. 1. 0.9% 1.4% 0.7%. 0.2%. 2.6%. 1.9%. 8.5%. 3.1%. 2.1%. 3.8%. 0.2%. 0. 0. 5. 7. 28. 7. 6. 10. 3. 0.9% 2.1% 0.0%. 0.0%. 1.2%. 1.6%. 6.6%. 1.6%. 1.4%. 2.4%. 0.7%. 3. 1. 37. 18. 90. 31. 23. 29. 11. 1.9% 3.5% 0.7%. 0.2%. 8.7%. 4.2%. 21.2%. 7.3%. 5.4%. 6.8%. 2.6%. 5. 3. 32. 3. 57. 59. 17. 26. 5. 1.3% 0.6% 0.6%. 0.4%. 3.8%. 0.4%. 6.7%. 7.0%. 2.0%. 3.1%. 0.6%. 3. 28. 2. 43. 114. 18. 37. 8. 4. 4. 8. 11. 15. 0. 6. 9. 15. 5. 13. 3. ! 81! !.

(89) 9.8% 0.2% 0.2%. 36~. 45. 1. 0. 5.3% 0.1% 0.0%. 219. 6. 8. 25.9% 0.7% 0.9%. 1.8% 1.5% 0.4%. 0.4%. 3.3%. 0.2%. 5.1%. 13.5%. 2.1%. 4.4%. 0.9%. 2. 1. 17. 3. 37. 26. 6. 6. 2. 0.6% 0.2% 0.2%. 0.1%. 2.0%. 0.4%. 4.4%. 3.1%. 0.7%. 0.7%. 0.2%. 10. 7. 77. 8. 137. 199. 41. 69. 15. 3.7% 2.4% 1.2%. 0.8%. 9.1%. 0.9%. 16.2%. 23.5%. 4.8%. 8.1%. 1.8%. 5. 31. 2. 20. ! 82! !.

(90) 4-3-9. n. :. n 53.671. 26. .001. 49.507. 26. .004. .011. -. .000. .01. -. .000. Tau. :. .335. .001. .235. .004. n 13-25. 36.562. 13. .000. 26-35. 55.336. 13. .000. 30.221. 13. .004. 36 Tau. 13-25. .008. .000. 26-35. .017. .000. .010. .000. 13-25. .272. .000. 26-35. .308. .000. .309. .000. 36. 36 <0.05. <0.01. :. :. :. <0.001. !. Health Belief Model susceptobility. 8 severity 3. 5. 8. benefit. t 8. cost. 8. : n u. 83! ! !. 3.

(91) 4-4-1. . .. d .. u. . (Remeron). d ,. 8 ,. e e. .. 8 , 6 ,. e. 3/? !: ,. 3 ,. l ,. !. ,. . , , anzepam. d ,. ,. d ,. u ,. , ,. a d .. : .... d. d ... 3 w. .... 84! ! !. d.

(92) ? .... A.M.D ?(. d ,. u. ). u. 3. d. 6 3. 8. 3. 3 8 9 Erispantab.0.2 ACETALTABLETMagHydroxideRouminColsin: u. d. ,. :. ,. .. .. ..... 2. d. ?. : : 011952 ? 35,. 152 ,. 51 ? 35 u :. 85! ! !.

(93) (. ). :. 5. ?? .... ??. 5. ~! t. : :. ???. :. u. 0 :. t. cataflam cataflam ? 6 amoxycillin ?. voren : ?. n u. w d. 8 4. d. n 4-4-2. n 13-25. :. ud u 26-35. 5 u. 6. 6 36. :. u 36. 86! ! !. :.

(94) u. 4-4-2. n. 13~25. 27 n. n. n. 5.9%. n. n. n. n 26~35 n. n. n. 87! ! !. 18.6% 24.5% 36. 63. 5.9%. 7.9%. 13.8%. 29. 71. 100. 6.3%. 9.4%. 15.5% 21.8% 106. 149. 23.1% 32.5%. 11. 43. 54. 2.4%. 9.4%. 11.8%. 8. 15. 23. 1.7%. 3.3%. 5.0%. 16. 31. 47. 3.5%. 6.8%. 10.3%. 3. 5. 8. 0.7%. 1.1%. 1.7%. 41. 113. 154. 7.8%. 21.4% 29.2%. 25. 39. 64. 4.7%. 7.4%. 12.1%. 43. 78. 121. 8.1% 45. n. 112. 27. 43 n. 85. 8.5%. 14.8% 22.9% 94. 139. 17.8% 26.3%.

(95) n. n. n. n 36~ n. n. n. 14. 51. 65. 2.7%. 9.7%. 12.3%. 8. 12. 20. 1.5%. 2.3%. 3.8%. 26. 60. 86. 4.9% 4. 8. 12. 0.8%. 1.5%. 2.3%. 31. 33. 64. 10.8% 11.5% 22.4% 16. 18. 34. 5.6%. 6.3%. 11.9%. 31. 44. 75. 10.8% 15.4% 26.2% 46. n. n. n. n. n. 88! ! !. 11.4% 16.3%. 45. 91. 16.1% 15.7% 31.8% 3. 10. 13. 1.0%. 3.5%. 4.5%. 6. 4. 10. 2.1%. 1.4%. 3.5%. 18. 28. 46. 6.3%. 9.8%. 16.1%. 1. 4. 5. 0.3%. 1.4%. 1.7%.

(96) 0. n n t. :. t 4-4-3 0n !=-.075. 0. p=.008. 5 t t. 4-4-3 t .008. t. p<0.05. 0.48 6 0.22 6 0.78 6. 0.45 1 0.82 1 0.66 2 0.79 7. .008 0.451 -. 0.486 0.821. 0.226 0.662. 0.786 0.797. -. -. -. -. -. -. -. -. -. -. -. -. -. -. p<0.01. 2 t n. n Rutten, Arora, Bakos, Aziz & Rowland, 2005. 89! ! !.

(97) 26-35. 328/. /26-35. n n. 20-. d. 29 2001. : d. :. :. 2016 :. n. n 5 n. 5. 5 13-25 36. 26-35. 5 8. n. 90! ! !. 26-35.

(98) 2 !. ! 5. 5. d. n. n. n 0 !. :. E n. :. n n. u5. n 9. 90-96 75-85. 8 2-3. 0. u. n. : 13-25. d. u5. 5. 36. 36. 5. 26-35. 5. :. 91! ! !. :.

(99) u. n. 5 13-25 26-35. 36. 26-35. 5 8. n. d. nn. d. n 13-25. 5 26-35 36. 8. : 26-35. u. 2. ud 13-25. 26-35 36. u. : 13-25. 26-35 36. u. : u. h. 92! ! !.

(100) 5. n. E t n. d. 0. 5. :. n 6. :. 5 5. .. n. :. d. 0 :. 93! ! !.

(101) Off-Label Use 3. 0. d. n. :. 5. :. 0 d. n. d : u. n. :. :. d :. d. n. : c. 0. n 0. 5. : n. :. d. t. :. u. d :. 94! ! !. n n.

(102) n. 5 n. n :. 5 5. 95! ! !.

(103) h !. ! 2. ,. ,. ,. ,. ,. 2016 24(1). 5 33-41 2003. :. http://nhuir.nhu.edu.tw/handle/987654321/21348 2002 http://ir.kmu.edu.tw/handle/310902000/21740 2001. 2008. -. http://handle.ncl.edu.tw/11296/ndltd/51728968512109876172 2016 p. 2015. 9. 14(2). 127-135. 24. https://anntw.com/articles/20150924-WRT7 2000 http://terms.naer.edu.tw/detail/1309109/ 2000 http://terms.naer.edu.tw/detail/1313455/ 2012 http://handle.ncl.edu.tw/11296/ndltd/08269055367791798243 2009 13(5). d. 449-460.. 2007 http://handle.ncl.edu.tw/11296/ndltd/20163487020950717234 &. 2016 p. 3. 1. 5. 177-201. 96! ! !.

(104) 2008. e. http://handle.ncl.edu.tw/11296/ndltd/45757592978046177604 2007. ,. e. http://handle.ncl.edu.tw/11296/ndltd/52614818205044129333 (2010). : :e 18. p. 151-191. 2004. http://handle.ncl.edu.tw/11296/ndltd/79278372907767593823 2012. 1. 20 !!. e. http://health.gov.taipei/Default.aspx?tabid=736&mid=2468&itemid=28897 2002. 1. 11. 2009. ─:. http://handle.ncl.edu.tw/11296/ndltd/07076850321433462591 t. 2015. 103-104. 5. e. http://ttw3.mmh.org.tw/safe/download/safe_2c_103.pdf 5. 2002 5. /. 1-3. Ascione, F. J., Kirscht, J. P., & Shimp, L. A. (1986). An assessment of different components of patient medication knowledge. Medical Care, 24(11), 1018-1028. Baker, S. J. (1997). Who can read consumer product information? The Australian Journal of Hospital Pharmacy, 27(2), 126-131. Bandesha, G., Raynor, D. K., & Teale, C. (1996). Preliminary investigation of patient information leaflets as package inserts. International Journal of Pharmacy Practice, 4(4), 246-248.. 97! ! !.

(105) Barak, A., & Grohol, J. M. (2011). Current and future trends in internet-supported mental health interventions. Journal of Technology in Human Services, 29(3), 155-196. Berelson, B. (1952). Content Analysis in Communication Research. NY: Free Press. Blackwell, B. (1972). The drug defaulter. Clinical Pharmacology & Therapeutics, 13(6), 841-848. Cockerham, W. C. (2004). Medical sociology. NJ : Prentice Hall Covington, T.R. (2004). Self-care and nonprescription pharmacotherapy. In Handbook of Nonprescription (pp. 3-14). Washington, DC: American Pharmaceutical Association. Crichton, E. F., Smith, D. L., & Demanuele, F. (1978). Patient recall of medication information. Drug intelligence & clinical pharmacy, 12(10), 591-599. Crummy. (2012). Beautiful Soup is licensed under the same terms as Python itself. Retrieved from https://www.crummy.com/software/BeautifulSoup/#Download Davis, T. C., Wolf, M. S., Bass, P. F., Middlebrooks, M., Kennen, E., Baker, D. W., ... & Parker, R. M. (2006). Low literacy impairs comprehension of prescription drug warning labels. Journal of general internal medicine, 21(8), 847-851. Deering, M. J., & Harris, J. (1996). Consumer health information demand and delivery: implications for libraries. Bulletin of the Medical Library Association, 84(2), 209. Downe,Wamboldt, B. (1992). Content analysis: method, applications, and issues. Health care for women international, 13(3), 313-321. Fox, S., & Duggan, M. (2013). Health Online 2013. Retrieved from http://bibliobase.sermais.pt:8008/BiblioNET/Upload/PDF5/003820.pdf Fraenkel, J.R. & Wallen, N.E.(1996). How to design and evaluate research in education (3rd. ed.). NY: McGraw-Hill. Gazmararian, J. A., Baker, D. W., Williams, M. V., Parker, R. M., Scott, T. L., Green, D. C., ... & Koplan, J. P. (1999). Health literacy among Medicare enrollees in a managed care organization. JAMA, 281(6), 545-551. Grunwald, M., & Wesemann, D. (2007). Special online consulting for patients with eating disorders and their relatives: Analysis of user characteristics and e-mail content. CyberPsychology & Behavior, 10(1), 57-63. Harris, L. M. (1995). Differences that make a difference. Health and the new media: Technologies transforming personal and public health, 163-183. 98! ! !.

(106) Haynes, R. B., Taylor, D. W., & Sackett, D. L. (1979). Compliance in Health Care. NY: Armonk Hepler, C. D., & Strand, L. M. (1990). Opportunities and responsibilities in pharmaceutical care. Am J hosp pharm, 47(3), 533-543. Hermann, F., Herxheimer, A., & Lionel, N. D. (1978). Package inserts for prescribed medicines: what minimum information do patients need? Br Med J, 2(6145), 1132-1135. Holt, G. A., & Hall, E. L. (1993). The self-care movement. In Handbook of Nonprescription Drugs (10th. Ed.). (pp. 1-9). Washington, DC: American Pharmaceutical Association. Houldin, A. D. (2007). A qualitative study of caregivers' experiences with newly diagnosed advanced colorectal cancer. Oncology nursing forum, 34(2), 332-330. Hsieh, H. F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. Qualitative health research, 15(9), 1277-1288. Hussar, D. A. (1975). Pharmacy practice--the importance of effective communications. American journal of pharmacy and the sciences supporting public health, 148(5), 136-147. Koo, M., Krass, I., & Aslani, P. (2006). Enhancing patient education about medicines: factors influencing reading and seeking of written medicine information. Health Expectations, 9(2), 174-187. Krippendorff, K. (1980). Content analysis: An introduction to its methodology. Los Angeles, CA:Sage. Lee, P. R. (1979). Prescription drug use and patient education--the critical role of the pharmacist. American journal of pharmaceutical education, 43(4), 354. MacLaughlin, E. J., Raehl, C. L., Treadway, A. K., Sterling, T. L., Zoller, D. P., & Bond, C. A. (2005). Assessing medication adherence in the elderly. Drugs & Aging, 22(3), 231-255. Makoul, G., Arntson, P., & Schofield, T. (1995). Health promotion in primary care: physician-patient communication and decision making about prescription medications. Social science & medicine, 41(9), 1241-1254. Monnier, J., Laken, M., & Carter, C. L. (2002). Patient and Caregiver Interest in Internet,Based Cancer Services. Cancer practice, 10(6), 305-310. doi: 10.1046/j.1523-5394.2002.106005.x 99! ! !.

(107) Morris, L. A., & Halperin, J. A. (1979). Effects of written drug information on patient knowledge and compliance: a literature review. American Journal of Public Health, 69(1), 47-52. Morris, L. A., Grossman, R., Barkdoll, G., & Gordon, E. (1987). A Segmentational Analysis of Prescription Drug Information Seeking. Medical Care, 25(10), 953964. Nair, K., Dolovich, L., Cassels, A., McCormack, J., Levine, M., Gray, J., ... & Burns, S. (2002). What patients want to know about their medications. Focus group study of patient and clinician perspectives. Canadian Family Physician, 48(1), 104-110. Nichols-English, G., & Poirier, S. (2000). Optimizing adherence to pharmaceutical care plans. J Am Pharm Assoc, 40(4), 475-475. Oh, S., Yi, Y. J., & Worrall, A. (2012). Quality of health answers in social Q&A. Proceedings of the Association for Information Science and Technology, 49(1), 16. Raynor, D. K., Savage, I., Knapp, P., & Henley, J. (2004). We are the experts: people with asthma talk about their medicine information needs. Patient education and counseling, 53(2), 167-174. Redestam, K.E., Newton, R.R. (1992). Surviving your dissertation: A comprehensive guide to content and process. Newbury Park, CA:SAGE. Renahy, E., Parizot, I., & Chauvin, P. (2010). Determinants of the frequency of online health information seeking: results of a web-based survey conducted in France in 2007. Informatics for Health and Social Care, 35(1), 25-39. Rice, R. E. (2006). Influences, usage, and outcomes of Internet health information searching: multivariate results from the Pew surveys. International journal of medical informatics, 75(1), 8-28. Rutten, L. J. F., Arora, N. K., Bakos, A. D., Aziz, N., & Rowland, J. (2005). Information needs and sources of information among cancer patients: a systematic review of research (1980–2003). Patient education and counseling, 57(3), 250-261. Sabaté, E. (2003). Adherence to long-term therapies: Evidence for action. World Health Organization. Geneva, Switzerland. Sangl, J. A., & Wolf, L. F. (1996). Role of consumer information in today's health care system. Health Care Financing Review, 18(1), 1.. 100! ! !.

(108) Schillinger, D., Grumbach, K., Piette, J., Wang, F., Osmond, D., Daher, C., ... & Bindman, A. B. (2002). Association of health literacy with diabetes outcomes. Jama, 288(4), 475-482. Shah, C., Oh, S., & Oh, J. S. (2009). Research agenda for social Q&A. Library & Information Science Research, 31(4), 205-209. Shrensky, R., & Sless, D. (2008). Choosing the right method for testing. Retrieved from http://www.communication.org.au/criapublications/publication_id_94_21143335 09. html. Spink, A., Yang, Y., Jansen, J., Nykanen, P., Lorence, D. P., Ozmutlu, S., & Ozmutlu, H. C. (2004). A study of medical and health queries to web search engines. Health Information & Libraries Journal, 21(1), 44-51. Strauss, A., & Corbin, J. (1998). Basics of qualitative research: Techniques and procedures for developing grounded theory. NY: Sage Publications, Inc. The American College of Physicians Foundation. (2007). Improving Prescription Drug Container. Labeling. in. the. United. States.. Retrieved. from:. http://www.nap.edu/catalog/12077.html Tuckman, B.W.(1994). Conducting Educational Research (4th ed.). Forth Worth, TX:Harcourt Brace & Company. Vander Stichele, R. H., Van Haecht, C. H., Braem, M. D., & Bogaert, M. G. (1991). Attitude of the public toward technical package inserts for medication information in Belgium. Annals of Pharmacotherapy, 25(9), 1002-1006. Wallace, L. S., Roskos, S. E., & Weiss, B. D. (2006). Readability characteristics of consumer medication information for asthma inhalation devices. Journal of Asthma, 43(5), 375-378. Webb, J., Davis, T. C., Bernadella, P., Clayman, M. L., Parker, R. M., Adler, D., & Wolf, M. S. (2008). Patient-centered approach for improving prescription drug warning labels. Patient education and counseling, 72(3), 443-449. WiseGeek. (2015). How do I get an Online Pharmacy Consultation? Retrieved from http://www.wisegeek.com/how-do-i-get-an-online-pharmacy-consultation.htm Wolf, M. S., Davis, T. C., Tilson, H. H., Bass III, P. F., & Parker, R. M. (2006). Misunderstanding of prescription drug warning labels among patients with low literacy. American Journal of Health-System Pharmacy, 63(11). World Health Organization. (2003). WHO Expert Committee on Drug Dependence : thirty-third report. Geneva : World Health Organization. 101! ! !.

(109) Zeman, S. E. (2001). Regulation of online pharmacies: a case for cooperative federalism. Annals Health L, 10(1), 105-137. Zhang, Y. (2010). Contextualizing consumer health information searching: an analysis of questions in a social Q&A community. In Proceedings of the 1st ACM International Health Informatics Symposium (pp. 210-219). ACM.. 102! ! !.

(110)